Bempedoic Acid and Ezetimibe for the Primary Prevention of Coronary Heart disease in the Statin-intolerant Patient: A Cost-effectiveness Analysis From the Australian Healthcare Perspective

The combination of bempedoic acid and ezetimibe (BE) is an effective way to reduce LDL-C and thus lower coronary heart disease (CHD) risk. However, at what cost this combination would be cost-effective in a primary prevention population is unknown. We estimated the maximum cost at which BE would remain cost-effective if initiated at age 40 years, by sex and LDL-C.